IL0006290147
IL0006290147
TEVA PHARMA IND
Loading chart...
Elevated Business & Solvency Risk
Caution: In addition to price volatility, there are balance sheet risks due to higher debt or weaker liquidity (Health Score: 50/100).
Volatility Risk
Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.
Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta
Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.8x).
Beta (Market Relation)
0.82x
DefensiveVolatility (5Y p.a.)
44.2% p.a.
5-Year HorizonMax Drawdown (5Y)
-40.5%
5-Year HorizonSharpe Ratio
0.60
Return / RiskSpeculative / High Risk: Score Basis:
Multi-Horizon Risk & Performance Matrix
Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.
High Volatility
Timeframe | Volatility (p.a.) | Max Drawdown | Sharpe Ratio | Return (p.a.) |
|---|---|---|---|---|
| 1 Year | — | — | — | +75.4% |
| 3 Years | 40.3% | -40.5% | 1.14 | +48.3% |
| 5 Years | 44.2% | -40.5% | 0.6 | +29.2% |
| 10 Years | 49.9% | -87.4% | -0.13 | -3.8% |
Automated Risk & Health Notes (Red Flags)
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Critical leverage: Debt-to-Equity is at 218%.
🔴 High valuation risk: Avg P/E of 62.8 (Elevated multiple compression risk)
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (44.2% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -87.4% in the extended horizon.
Corporate Governance & ISS Scores
Overall Governance Risk
4 ISS Score: 4 / 10
Audit Risk
8 ISS Score: 8 / 10
Board Risk
3 ISS Score: 3 / 10
Short Ratio
-